<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39327617</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2042-6410</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Biology of sex differences</Title><ISOAbbreviation>Biol Sex Differ</ISOAbbreviation></Journal><ArticleTitle>Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study.</ArticleTitle><Pagination><StartPage>74</StartPage><MedlinePgn>74</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">74</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13293-024-00651-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sex differences exist not only in the efficacy but also in adverse event rates of many vaccines. Here we compared the safety of BNT162b2 vaccine administered off-label in female and male children younger than 5 years in Germany.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective cohort study, in which we performed a post-hoc analysis of a dataset collected through an authentication-based survey of individuals having registered children aged 0-&lt;5 years for vaccination against SARS-CoV-2 in six private practices and/or two lay person-initiated vaccination campaigns. We analyzed the safety profiles of the first 3 doses of 3-10 µg BNT162b2. Primary outcome was comparison in frequencies of 4 common post-vaccination symptom categories such as local, general, musculoskeletal symptoms and fever. Data were analyzed according to sex in bivariate analyses and regression models adjusting for age, weight, and dosage. Interaction between sex and BNT162b2 dosage was assessed. An active-comparator analysis was applied to compare post-vaccination symptoms after BNT162b2 versus non-SARS-CoV-2 vaccines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The dataset for the present analysis consisted of 7801 participants including 3842 females (49%) and 3977 males (51%) with an age of 3 years (median, interquartile: 2 years). Among individuals receiving 3 µg BNT162b2, no sex differences were noted, but after a first dose of 5-10 µg BNT162b2, local injection-site symptoms were more prevalent in girls compared to boys. In logistic regression, female sex was associated with higher odds of local symptoms, odds ratio (OR) of 1.33 (95% confidence interval [CI]: 1.15-1.55, p &lt; 0.05) and general symptoms with OR 1.21 (95% CI: 1.01-1.44, p &lt; 0.05). Following non-BNT162b2 childhood vaccinations, female sex was associated with a lower odds of post-vaccination musculoskeletal symptoms (OR: 0.29, 95% CI: 0.11-0.82, p &lt; 0.05). An active comparator analysis between BNT162b2 and non-SARS-CoV-2 vaccinations revealed that female sex positively influenced the association between BNT162b2 vaccine type and musculoskeletal symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sex differences exist in post-vaccination symptoms after BNT162b2 administration even in young children. These are of importance for the conception of approval studies, for post-vaccination monitoring and for future vaccination strategies (German Clinical Trials Register ID: DRKS00028759).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moor</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CLINTEC Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toepfner</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Meißner</LastName><ForeName>Wolfgang C G</ForeName><Initials>WCG</Initials><AffiliationInfo><Affiliation>Europäische Fachhochschule, Brühl, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Family Medicine, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berner</LastName><ForeName>Reinhard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moor</LastName><ForeName>Matthias B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>CLINTEC Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABMED Division of Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kublickiene</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>CLINTEC Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strumann</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Family Medicine, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Cho-Ming</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Helios University Medical Center, Witten/Herdecke University, Heusnerstraße 40, 42283, Wuppertal, Germany. cho-ming.chao@helios-gesundheit.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Children's Hospital, University Medical Center Rostock, University of Rostock, Rostock, Germany. cho-ming.chao@helios-gesundheit.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Justus Liebig University Giessen, Giessen, Germany. cho-ming.chao@helios-gesundheit.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biol Sex Differ</MedlineTA><NlmUniqueID>101548963</NlmUniqueID><ISSNLinking>2042-6410</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>For many childhood vaccines, the immune responses are different between the sexes. For the COVID-19 vaccine BNT162b2, the symptoms occurring after vaccination in children have not sufficiently been investigated. In this study, we performed an analysis of a dataset of retrospectively collected information on symptoms occurring after vaccinations with BNT162b2 and regular childhood vaccines in 7801 children under the age of 5 years in Germany, with a focus on the sex differences. Among the four categories assessed, local injection-site and general symptoms were more frequent in girls compared to boys. In contrast, following the administration of other childhood vaccines, the caregivers more frequently reported muscle-related symptoms in boys than in girls. In conclusion, sex differences exist in symptoms occurring after vaccinations even in young children, which is important to consider for future studies evaluating vaccine safety.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Sex difference</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39327617</ArticleId><ArticleId IdType="pmc">PMC11426002</ArticleId><ArticleId IdType="doi">10.1186/s13293-024-00651-x</ArticleId><ArticleId IdType="pii">10.1186/s13293-024-00651-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fehervari Z. Vaccine sex differences. Nat Immunol. 2019;20(2):111–111.</Citation><ArticleIdList><ArticleId IdType="pubmed">30664761</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SL, Jedlicka A, Pekosz A. The xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6467501</ArticleId><ArticleId IdType="pubmed">20417416</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects vaccine efficacy and protection against influenza in mice. Proc Natl Acad Sci U S A. 2018;115(49):12477–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298067</ArticleId><ArticleId IdType="pubmed">30455317</ArticleId></ArticleIdList></Reference><Reference><Citation>Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiébaut R, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111(2):869–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896147</ArticleId><ArticleId IdType="pubmed">24367114</ArticleId></ArticleIdList></Reference><Reference><Citation>Rettew JA, Huet-Hudson YM, Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biol Reprod. 2008;78(3):432–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18003947</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Agostino P, Milano S, Barbera C, Di Bella G, La Rosa M, Ferlazzo V, et al. Sex hormones modulate inflammatory mediators produced by macrophages. Ann N Y Acad Sci. 1999;876:426–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10415638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignucolo A, Scarabel L, Mezzalira S, Polesel J, Cecchin E, Toffoli G. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and Meta-analysis. Vaccines. 2021;9(8):825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402482</ArticleId><ArticleId IdType="pubmed">34451950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen A, Stromme M, Moyassari S, Chadha AS, Tartaglia MC, Szoeke C, et al. COVID-19 vaccines: considering sex differences in efficacy and safety. Contemp Clin Trials. 2022;115:106700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824304</ArticleId><ArticleId IdType="pubmed">35149232</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro JR, Sitaras I, Park HS, Aytenfisu TY, Caputo C, Li M, et al. Association of Frailty, Age, and biological sex with severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA vaccine–Induced immunity in older adults. Clin Infect Dis. 2022;75(Supplement1):S61–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9376280</ArticleId><ArticleId IdType="pubmed">35607747</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017;33(1):577–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">28992436</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990–2016. J Allergy Clin Immunol. 2019;143(4):1465–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580415</ArticleId><ArticleId IdType="pubmed">30654049</ArticleId></ArticleIdList></Reference><Reference><Citation>Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risk of Myocarditis after sequential doses of COVID-19 vaccine and SARS-CoV-2 infection by Age and Sex. Circulation. 2022;146(10):743–54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9439633</ArticleId><ArticleId IdType="pubmed">35993236</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassallo A, Shajahan S, Harris K, Hallam L, Hockham C, Womersley K, et al. Sex and gender in COVID-19 Vaccine Research: substantial evidence gaps remain. Front Glob Womens Health. 2021;2:761511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8593988</ArticleId><ArticleId IdType="pubmed">34816252</ArticleId></ArticleIdList></Reference><Reference><Citation>Duijster JW, Lieber T, Pacelli S, Van Balveren L, Ruijs LS, Raethke M, et al. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: a Dutch cohort study and review of the literature. Front Immunol. 2023;14:1078736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9922710</ArticleId><ArticleId IdType="pubmed">36793715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori M, Yokoyama A, Shichida A, Sasuga K, Maekawa T, Moriyama T. Impact of sex and age on mRNA COVID-19 vaccine-related side effects in Japan. Microbiol Spectr. 2022;10(6):e0130922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769945</ArticleId><ArticleId IdType="pubmed">36314943</ArticleId></ArticleIdList></Reference><Reference><Citation>Green MS, Peer V, Magid A, Hagani N, Anis E, Nitzan D. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines. 2022;10(2):233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875740</ArticleId><ArticleId IdType="pubmed">35214694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First Month of COVID-19 Vaccine Safety monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(8):283–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344985</ArticleId><ArticleId IdType="pubmed">33630816</ArticleId></ArticleIdList></Reference><Reference><Citation>Toepfner N, von Meißner WCG, Strumann C, Drinka D, Stuppe D, Jorczyk M, et al. Comparative safety of the BNT162b2 Messenger RNA COVID-19 vaccine vs other approved vaccines in children younger than 5 years. JAMA Netw Open. 2022;5(10):e2237140–2237140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9579908</ArticleId><ArticleId IdType="pubmed">36255723</ArticleId></ArticleIdList></Reference><Reference><Citation>Strumann C, Ranzani O, Moor J, Berner R, Töpfner N, Chao CM, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years. J Clin Invest. 2023;133(21):e173329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10617758</ArticleId><ArticleId IdType="pubmed">37669113</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Ren W, Wu T, Wang Q, Luo M, Yi Y, et al. Real-world safety of COVID-19 mRNA vaccines: a systematic review and Meta-analysis. Vaccines. 2023;11(6):1118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10301865</ArticleId><ArticleId IdType="pubmed">37376508</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook IF. Sex differences in injection site reactions with human vaccines. Hum Vaccin. 2009;5(7):441–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19377279</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiely M, Tadount F, Lo E, Sadarangani M, Wei SQ, Rafferty E, et al. Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials. J Epidemiol Community Health. 2023;77(12):791–801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10646905</ArticleId><ArticleId IdType="pubmed">37734937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hause AM, Marquez P, Zhang B, Moro PL, Myers TR, Bradley C, et al. Safety Monitoring of mRNA COVID-19 vaccine third doses among children aged 6 Months-5 years - United States, June 17, 2022-May 7, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(23):621–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10328461</ArticleId><ArticleId IdType="pubmed">37289661</ArticleId></ArticleIdList></Reference><Reference><Citation>Muñoz FM, Sher LD, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al. Evaluation of BNT162b2 Covid-19 vaccine in children younger than 5 years of age. N Engl J Med. 2023;388(7):621–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9947923</ArticleId><ArticleId IdType="pubmed">36791162</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccines and Related Biological Products Advisory Committee June 14–15. 2022 Meeting Briefing Document- FDA- Pfizer- COVID19 Vaccine for Pediatrics | FDA [Internet]. [cited 2023 Apr 17]. https://www.fda.gov/media/159195/download</Citation></Reference><Reference><Citation>Aaby P, Benn CS, Flanagan KL, Klein SL, Kollmann TR, Lynn DJ, et al. The non-specific and sex-differential effects of vaccines. Nat Rev Immunol. 2020;20(8):464–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252419</ArticleId><ArticleId IdType="pubmed">32461674</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaby P, Ravn H, Fisker AB, Rodrigues A, Benn CS. Is diphtheria-tetanus-pertussis (DTP) associated with increased female mortality? A meta-analysis testing the hypotheses of sex-differential non-specific effects of DTP vaccine. Trans R Soc Trop Med Hyg. 2016;110(10):570–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5155548</ArticleId><ArticleId IdType="pubmed">27856947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences and age. Womens Health Lond Engl. 2021;17:17455065211022262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8188967</ArticleId><ArticleId IdType="pubmed">34096383</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Lee A, Grigoryan L, Arunachalam PS, Scott MKD, Trisal M, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022;23(4):543–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989677</ArticleId><ArticleId IdType="pubmed">35288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021;31(7):818–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021;22(7):829–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts BJ, Moussawi M, Huber SA. Sex differences in TLR2 and TLR4 expression and their effect on coxsackievirus-induced autoimmune myocarditis. Exp Mol Pathol. 2013;94(1):58–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485413</ArticleId><ArticleId IdType="pubmed">22750431</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaoglan M, Nacarkahya G. Immunological interpretation of minipuberty: Minipuberty as the driving force of sexual dimorphism in the immune response. Clin Endocrinol (Oxf). 2021;94(4):575–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">33278840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Sa S, Hong M, Kim J, Shim SR, Han HW. Adverse events and Safety Profile of the COVID-19 vaccines in adolescents: Safety Monitoring for adverse events using real-World Data. Vaccines. 2022;10(5):744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9143867</ArticleId><ArticleId IdType="pubmed">35632500</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>